— Optumrx, the world’s leading drugmaker of prescription drugs, will buy Pharmacy Rx for $5.6 billion in a deal that also includes the rights to other brands of the company’s products, including the asthma drug Emory, the deal announced Tuesday.
Pharmacy Rx, the pharmacy-drug maker’s specialty brand, has seen an explosive growth in recent years, and it has been a focus for the U.S. Drug Enforcement Administration and the federal government, including a number of antitrust lawsuits.
Pharmaceutically, Pharmacy has seen its share price rise as it has acquired new brands.
The pharmacy-brand name Emory surged 14% last year to a record high of $2.6 trillion, and the company has been in the news for some of its drug launches.
The company has also been on the front line in the fight against the opioid epidemic, winning a $1.5 billion settlement with the Federal Trade Commission over charges that its products were linked to the deaths of two people.
As a result, it has faced criticism that it is too close to the pharmaceutical industry and should be treated differently.
“This transaction is a significant win for consumers in our region and a significant investment in our future,” said Phytos Corporation Chairman John D. Dias.
“Pharmacies have been the key partners for millions of people and we look forward to continuing to grow pharmacy revenues and drive growth in our businesses and for our employees.”
The deal is a win for everyone involved, said Pharmacy CEO Kevin S. DeMint.
It’s an exciting day for all of us, he said.
We are excited to continue our partnership with Pharmacy.
We believe in the power of the pharmacy and believe it can play a pivotal role in the lives of our customers.
We are also grateful for the support of the Pharmacy Board of Directors and our customers, which has helped us make this transaction happen.
Apharma is a drug company, which is a private company.
It does not have a stock-based compensation plan, which means that it does not give shareholders stock options or other rights.
The deal was expected to close by the end of the year, and pharmacy stocks have already surged.
The stock gained more than 7% after the announcement.
Pharmacists will continue to be able to access their pharmacy prescription and receive Emory’s asthma drug, as well as a number more new products.
The deal includes Emory as a Pharmacy Exclusive.
The transaction also includes an undisclosed amount of other assets including intellectual property and a small minority stake in Pharmacy’s board of directors.
Phytos is also an equity investor in Pharmaceutical, and shares of Pharmaceutical will be valued at $6 billion.
PhytoSys, which had a valuation of $5 billion in its previous transaction, is a biotechnology company based in California.
The company developed a drug that helps treat asthma, and has received a patent on the drug in the U., Canada, the U and South Korea.
PhymistoSys has also received a number other awards from the U-M School of Pharmacy and has been named a top 10 pharmacy for 2018 by the Chronicle of Philanthropy.